Introduction: Pituitary neuroendocrine tumors (PitNETs), the most abundant of all intracranial tumors, entail severe comorbidities. First-line therapy is transsphenoidal surgery, but subsequent pharmacological therapy is often required. Unfortunately, many patients are/become unresponsive to available drugs (somatostatin analogues [SSAs]/dopamine agonists), underscoring the need for new therapies. Statins are well-known drugs commonly prescribed to treat hyperlipidemia/cardiovascular diseases, but can convey additional beneficial effects, including antitumor actions. The direct effects of statins on normal human pituitary or PitNETs are poorly known. Thus, we aimed to explore the direct effects of statins, especially simvastatin, on key functional parameters in normal and tumoral pituitary cells, and to evaluate the combined effects of simvastatin with metformin (MF) or SSAs. Methods: Effects of statins in cell proliferation/viability, hormone secretion, and signaling pathways were evaluated in normal pituitary cells from a primate model (Papio anubis), tumor cells from corticotropinomas, somatotropinomas, nonfunctioning pituitary tumors, and PitNET cell-lines (AtT20/GH3-cells). Results: All statins decreased AtT20-cell proliferation, simvastatin showing stronger effects. Indeed, simvastatin reduced cell viability and/or hormone secretion in all PitNETs subtypes and cell-lines, and ACTH/GH/PRL/FSH/LH secretion (but not expression), in primate cell cultures, by modulating MAPK/PI3K/mTOR pathways and expression of key receptors (GH-releasing hormone-receptor/ghrelin-R/Kiss1-R) regulating pituitary function. Addition of MF or SSAs did not enhance simvastatin antitumor effects. Conclusion: Our data reveal direct antitumor effects of simvastatin on PitNET-cells, paving the way to explore these compounds as a possible tool to treat PitNETs.

1.
Mete
O
,
Lopes
MB
.
Overview of the 2017 WHO Classification of Pituitary Tumors
.
Endocr Pathol
.
2017
Sep
;
28
(
3
):
228
43
.
[PubMed]
1046-3976
2.
Molitch
ME
.
Diagnosis and Treatment of Pituitary Adenomas: A Review
.
JAMA
.
2017
Feb
;
317
(
5
):
516
24
.
[PubMed]
0098-7484
3.
Asa
SL
,
Ezzat
S
.
The pathogenesis of pituitary tumors
.
Annu Rev Pathol
.
2009
;
4
(
1
):
97
126
.
[PubMed]
1553-4006
4.
Colao
A
,
Savastano
S
.
Medical treatment of prolactinomas
.
Nat Rev Endocrinol
.
2011
May
;
7
(
5
):
267
78
.
[PubMed]
1759-5029
5.
Hofland
LJ
,
Feelders
RA
,
de Herder
WW
,
Lamberts
SW
.
Pituitary tumours: the sst/D2 receptors as molecular targets
.
Mol Cell Endocrinol
.
2010
Sep
;
326
(
1-2
):
89
98
.
[PubMed]
0303-7207
6.
Colao
A
,
Auriemma
RS
,
Pivonello
R
.
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
.
Pituitary
.
2016
Apr
;
19
(
2
):
210
21
.
[PubMed]
1386-341X
7.
Theodoropoulou
M
,
Stalla
GK
.
Somatostatin receptors: from signaling to clinical practice
.
Front Neuroendocrinol
.
2013
Aug
;
34
(
3
):
228
52
.
[PubMed]
0091-3022
8.
Colao
A
,
Auriemma
RS
,
Lombardi
G
,
Pivonello
R
.
Resistance to somatostatin analogs in acromegaly
.
Endocr Rev
.
2011
Apr
;
32
(
2
):
247
71
.
[PubMed]
0163-769X
9.
Gazzerro
P
,
Proto
MC
,
Gangemi
G
,
Malfitano
AM
,
Ciaglia
E
,
Pisanti
S
, et al
Pharmacological actions of statins: a critical appraisal in the management of cancer
.
Pharmacol Rev
.
2012
Jan
;
64
(
1
):
102
46
.
[PubMed]
0031-6997
10.
Zhou
Q
,
Liao
JK
.
Pleiotropic effects of statins. - Basic research and clinical perspectives -
.
Circ J
.
2010
May
;
74
(
5
):
818
26
.
[PubMed]
1346-9843
11.
Wang
T
,
Seah
S
,
Loh
X
,
Chan
CW
,
Hartman
M
,
Goh
BC
, et al
Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway
.
Oncotarget
.
2016
Jan
;
7
(
3
):
2532
44
.
[PubMed]
1949-2553
12.
Jang
HJ
,
Hong
EM
,
Park
SW
,
Byun
HW
,
Koh
DH
,
Choi
MH
, et al
Statin induces apoptosis of human colon cancer cells and downregulation of insulin-like growth factor 1 receptor via proapoptotic ERK activation
.
Oncol Lett
.
2016
Jul
;
12
(
1
):
250
6
.
[PubMed]
1792-1074
13.
Jin
Y
,
Xu
K
,
Chen
Q
,
Wang
B
,
Pan
J
,
Huang
S
, et al
Simvastatin inhibits the development of radioresistant esophageal cancer cells by increasing the radiosensitivity and reversing EMT process via the PTEN-PI3K/AKT pathway
.
Exp Cell Res
.
2018
Jan
;
362
(
2
):
362
9
.
[PubMed]
0014-4827
14.
Fliedner
SM
,
Engel
T
,
Lendvai
NK
,
Shankavaram
U
,
Nölting
S
,
Wesley
R
, et al
Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells
.
PLoS One
.
2014
May
;
9
(
5
):
e97712
.
[PubMed]
1932-6203
15.
Hu
HJ
,
Zhou
SH
,
Liu
QM
.
Treatment of pheochromocytoma blockade of MAPK pathway inhibition in the NF-κB pathway and bFGF - effect of statins on pheochromocytoma patients
.
Int J Cardiol
.
2015
Mar
;
182
:
161
2
.
[PubMed]
0167-5273
16.
Herrera-Martinez
AD
,
Pedraza-Arevalo
S
, F LL, Gahete MD, Galvez-Moreno MA, Castano JP, et al.
Type 2 diabetes in neuroendocrine tumors: are biguanides and statins part of the solution?
J Clin Endocrinol Metab
.
2018
.
[PubMed]
0021-972X
17.
Zhong
S
,
Zhang
X
,
Chen
L
,
Ma
T
,
Tang
J
,
Zhao
J
.
Statin use and mortality in cancer patients: systematic review and meta-analysis of observational studies
.
Cancer Treat Rev
.
2015
Jun
;
41
(
6
):
554
67
.
[PubMed]
0305-7372
18.
Fujimoto
M
,
Higuchi
T
,
Hosomi
K
,
Takada
M
.
Association between statin use and cancer: data mining of a spontaneous reporting database and a claims database
.
Int J Med Sci
.
2015
Jan
;
12
(
3
):
223
33
.
[PubMed]
1449-1907
19.
Tsubaki
M
,
Takeda
T
,
Obata
N
,
Kawashima
K
,
Tabata
M
,
Imano
M
, et al
Combination therapy with dacarbazine and statins improved the survival rate in mice with metastatic melanoma
.
J Cell Physiol
.
2019
Aug
;
234
(
10
):
17975
89
.
[PubMed]
0021-9541
20.
McClure
HM
.
Nonhuman primate models for human disease
.
Adv Vet Sci Comp Med
.
1984
;
28
:
267
304
.
[PubMed]
0065-3519
21.
Comuzzie
AG
,
Cole
SA
,
Martin
L
,
Carey
KD
,
Mahaney
MC
,
Blangero
J
, et al
The baboon as a nonhuman primate model for the study of the genetics of obesity
.
Obes Res
.
2003
Jan
;
11
(
1
):
75
80
.
[PubMed]
1071-7323
22.
Vázquez-Borrego
MC
,
Fuentes-Fayos
AC
,
Gahete
MD
,
Castaño
JP
,
Kineman
RD
,
Luque
RM
.
The Pituitary Gland is a Novel Major Site of Action of Metformin in Non-Human Primates: a Potential Path to Expand and Integrate Its Metabolic Actions
.
Cell Physiol Biochem
.
2018
;
49
(
4
):
1444
59
.
[PubMed]
1015-8987
23.
van Hoek
M
,
Hofland
LJ
,
de Rijke
YB
,
van Nederveen
FH
,
de Krijger
RR
,
van Koetsveld
PM
, et al
Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies
.
J Clin Endocrinol Metab
.
2009
Feb
;
94
(
2
):
428
33
.
[PubMed]
0021-972X
24.
Ibáñez-Costa
A
,
Rivero-Cortés
E
,
Vázquez-Borrego
MC
,
Gahete
MD
,
Jiménez-Reina
L
,
Venegas-Moreno
E
, et al
Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro
.
J Endocrinol
.
2016
Nov
;
231
(
2
):
135
45
.
[PubMed]
0022-0795
25.
Ibáñez-Costa
A
,
López-Sánchez
LM
,
Gahete
MD
,
Rivero-Cortés
E
,
Vázquez-Borrego
MC
,
Gálvez
MA
, et al
BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas
.
Sci Rep
.
2017
Feb
;
7
(
1
):
42002
.
[PubMed]
2045-2322
26.
Luque
RM
,
Ibáñez-Costa
A
,
López-Sánchez
LM
,
Jiménez-Reina
L
,
Venegas-Moreno
E
,
Gálvez
MA
, et al
A cellular and molecular basis for the selective desmopressin-induced ACTH release in Cushing disease patients: key role of AVPR1b receptor and potential therapeutic implications
.
J Clin Endocrinol Metab
.
2013
Oct
;
98
(
10
):
4160
9
.
[PubMed]
0021-972X
27.
Ibáñez-Costa
A
,
Gahete
MD
,
Rivero-Cortés
E
,
Rincón-Fernández
D
,
Nelson
R
,
Beltrán
M
, et al
In1-ghrelin splicing variant is overexpressed in pituitary adenomas and increases their aggressive features
.
Sci Rep
.
2015
Mar
;
5
(
1
):
8714
.
[PubMed]
2045-2322
28.
Uphoff
CC
,
Drexler
HG
.
Detection of mycoplasma contaminations
.
Methods Mol Biol
.
2013
;
946
:
1
13
.
[PubMed]
1064-3745
29.
Kineman
RD
,
Luque
RM
.
Evidence that ghrelin is as potent as growth hormone (GH)-releasing hormone (GHRH) in releasing GH from primary pituitary cell cultures of a nonhuman primate (Papio anubis), acting through intracellular signaling pathways distinct from GHRH
.
Endocrinology
.
2007
Sep
;
148
(
9
):
4440
9
.
[PubMed]
0013-7227
30.
Luque
RM
,
Córdoba-Chacón
J
,
Gahete
MD
,
Navarro
VM
,
Tena-Sempere
M
,
Kineman
RD
, et al
Kisspeptin regulates gonadotroph and somatotroph function in nonhuman primate pituitary via common and distinct signaling mechanisms
.
Endocrinology
.
2011
Mar
;
152
(
3
):
957
66
.
[PubMed]
0013-7227
31.
Durán-Prado
M
,
Gahete
MD
,
Martínez-Fuentes
AJ
,
Luque
RM
,
Quintero
A
,
Webb
SM
, et al
Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors
.
J Clin Endocrinol Metab
.
2009
Jul
;
94
(
7
):
2634
43
.
[PubMed]
0021-972X
32.
Luque
RM
,
Kineman
RD
.
Neuronostatin exerts actions on pituitary that are unique from its sibling peptide somatostatin
.
J Endocrinol
.
2018
Jun
;
237
(
3
):
217
27
.
[PubMed]
0022-0795
33.
Środa-Pomianek
K
,
Michalak
K
,
Palko-Łabuz
A
,
Uryga
A
,
Szczęśniak-Sięga
B
,
Wesołowska
O
.
Simvastatin Strongly Augments Proapoptotic, Anti-inflammatory and Cytotoxic Activity of Oxicam Derivatives in Doxorubicin-resistant Colon Cancer Cells
.
Anticancer Res
.
2019
Feb
;
39
(
2
):
727
34
.
[PubMed]
0250-7005
34.
Chen
MC
,
Tsai
YC
,
Tseng
JH
,
Liou
JJ
,
Horng
S
,
Wen
HC
, et al
Simvastatin Inhibits Cell Proliferation and Migration in Human Anaplastic Thyroid Cancer
.
Int J Mol Sci
.
2017
Dec
;
18
(
12
):
E2690
.
[PubMed]
1661-6596
35.
Chen
Y
,
Li
LB
,
Zhang
J
,
Tang
DP
,
Wei
JJ
,
Zhuang
ZH
.
Simvastatin, but not pravastatin, inhibits the proliferation of esophageal adenocarcinoma and squamous cell carcinoma cells: a cell-molecular study
.
Lipids Health Dis
.
2018
Dec
;
17
(
1
):
290
.
[PubMed]
1476-511X
36.
Lee
M
,
Wiedemann
T
,
Gross
C
,
Leinhäuser
I
,
Roncaroli
F
,
Braren
R
, et al
Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas
.
Clin Cancer Res
.
2015
Jul
;
21
(
14
):
3204
15
.
[PubMed]
1078-0432
37.
Roof
AK
,
Gutierrez-Hartmann
A
.
Consider the context: Ras/ERK and PI3K/AKT/mTOR signaling outcomes are pituitary cell type-specific
.
Mol Cell Endocrinol
.
2018
Mar
;
463
:
87
96
.
[PubMed]
0303-7207
38.
Vázquez-Borrego
MC
,
Fuentes-Fayos
AC
,
Herrera-Martínez
AD
,
L-López
F
,
Ibáñez-Costa
A
,
Moreno-Moreno
P
, et al
Biguanides exert antitumoral actions in pituitary tumor cells through AMPK-dependent and -independent mechanisms
.
J Clin Endocrinol Metab
.
2019
Aug
;
104
(
8
):
3501
13
.
[PubMed]
0021-972X
39.
Zawada
NB
,
Kunert-Radek
J
,
Pawlikowski
M
,
Pisarek
H
,
Radek
M
.
An evaluation of the effects of somatostatin analogue therapy in non-functioning pituitary adenomas in comparison to acromegaly
.
Endokrynol Pol
.
2016
;
67
(
3
):
292
8
.
[PubMed]
2299-8306
40.
Luque
RM
,
Gahete
MD
,
Hochgeschwender
U
,
Kineman
RD
.
Evidence that endogenous SST inhibits ACTH and ghrelin expression by independent pathways
.
Am J Physiol Endocrinol Metab
.
2006
Aug
;
291
(
2
):
E395
403
.
[PubMed]
0193-1849
41.
Córdoba-Chacón
J
,
Gahete
MD
,
Castaño
JP
,
Kineman
RD
,
Luque
RM
.
Homologous and heterologous in vitro regulation of pituitary receptors for somatostatin, growth hormone (GH)-releasing hormone, and ghrelin in a nonhuman primate (Papio anubis)
.
Endocrinology
.
2012
Jan
;
153
(
1
):
264
72
.
[PubMed]
0013-7227
42.
Iannelli
F
,
Lombardi
R
,
Milone
MR
,
Pucci
B
,
De Rienzo
S
,
Budillon
A
, et al
Targeting Mevalonate Pathway in Cancer Treatment: repurposing of Statins
.
Recent Patents Anticancer Drug Discov
.
2018
;
13
(
2
):
184
200
.
[PubMed]
1574-8928
43.
Valea
A
,
Ghervan
C
,
Carsote
M
,
Morar
A
,
Iacob
I
,
Tomesc
F
, et al
Effects of combination therapy: somatostatin analogues and dopamine agonists on GH and IGF1 levels in acromegaly
.
Clujul Med
.
2015
;
88
(
3
):
310
3
.
[PubMed]
1222-2119
44.
Puig-Domingo
M
,
Soto
A
,
Venegas
E
,
Vilchez
R
,
Blanco
C
,
Cordido
F
, et al;
ACROCOMB study group
.
Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: the ACROCOMB study
.
Endocrinol Nutr
.
2016
Oct
;
63
(
8
):
397
408
.
[PubMed]
1575-0922
45.
Misirkic
M
,
Janjetovic
K
,
Vucicevic
L
,
Tovilovic
G
,
Ristic
B
,
Vilimanovich
U
, et al
Inhibition of AMPK-dependent autophagy enhances in vitro antiglioma effect of simvastatin
.
Pharmacol Res
.
2012
Jan
;
65
(
1
):
111
9
.
[PubMed]
1043-6618
46.
Wang
ST
,
Ho
HJ
,
Lin
JT
,
Shieh
JJ
,
Wu
CY
.
Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells
.
Cell Death Dis
.
2017
Feb
;
8
(
2
):
e2626
.
[PubMed]
2041-4889
47.
Wang
JC
,
Li
XX
,
Sun
X
,
Li
GY
,
Sun
JL
,
Ye
YP
, et al
Activation of AMPK by simvastatin inhibited breast tumor angiogenesis via impeding HIF-1α-induced pro-angiogenic factor
.
Cancer Sci
.
2018
May
;
109
(
5
):
1627
37
.
[PubMed]
1347-9032
48.
Cakir
M
,
Grossman
AB
.
Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis
.
Expert Opin Ther Targets
.
2009
Sep
;
13
(
9
):
1121
34
.
[PubMed]
1472-8222
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.